Articles

Poll

Podcasts

Slideshows

Videos

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

FDA Approves Palopegteriparatide for Hypoparathyroidism

Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.

Endocrinology Month in Review: May 2024

The FDA has extended the review period for palopegteriparatide in treatment of hyperparathyroidism in adult patients by 3 months to August 14, 2024. 

FDA Extends Review for TransCon PTH in Hypoparathyroidism to August 2024

A study suggests that opting for thyroid surgery or radioactive iodine therapy could be better for reducing long-term cardiovascular risk in hyperthyroidism patients compared to medication alone.

Thyroidectomy, Radioactive Iodine Could Prevent More CV Events than Antithyroid Drugs

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

Endocrinology Month in Review: December 2023

This endocrine case report from Brady Pregerson, MD, features a woman in her early 50s with a history of type 2 diabetes and hypothyroidism presenting with 5 days of epigastric pain. Can you determine the correct diagnosis?

Endocrine Case Report: Epigastric Pain in T2D and Hypothyroidism

Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level. 

Hypothyroidism Significantly Linked to Nephrotic Syndrome

Announced on December 04, 2023, the approved label changes allow for administration regardless of timing of proton pump administration and for administration 15 minutes before breakfast. 

FDA Approves New Label Changes for Tirosint-SOL, Expanding Administration Options

This endocrine case report from Brady Pregerson, MD, features a patients in his mid-70s with a history of hypothyroidism presenting with weeks of nausea, vomiting, and diarrhea without blood but with a 30-pound weight loss. Can you determine the most likely diagnosis? 

Endocrine Case Report: Diarrhea and Weight Loss

Data from the open-label extension portion of the phase 3 PaTHway trial detail the long-term effects of TransCon PTH use among people with chronic hypoparathyroidism.

Thyroid Disorders